Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect?

vTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid

AbbVie presented Phase 3 data showing RINVOQ's continued repigmentation benefits in non-segmental vitiligo through 76 weeks, with additional improvements when combined with NB-UVB phototherapy. Presented at the 2026 EADV Congress, the findings support RINVOQ's long-term use and potential combination therapies. RINVOQ is approved in the EU for vitiligo and under U.S. review.

Citi initiated coverage on Rocket Lab (RKLB) with a Buy rating and $105 price target, citing its strong position in the commercial space launch sector and expanding mission backlog. RKLB's P/S ratio is 54.46x, above historical levels, reflecting growth expectations. The company has a GF Score of 73/100, indicating solid fundamentals despite profitability challenges. Insiders have sold $673.3 million in shares over the past year.

Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.

Deutsche Bank raised its price target for Synopsys (SNPS) to $640 from $590 after the company announced multiyear deals with Amazon and OpenAI. The partnerships are expected to boost revenue growth and innovation in AI-driven chip design. Synopsys's fiscal 2027 guidance includes 15% revenue growth to $11.15 billion, with an adjusted operating margin of 44% and adjusted EPS near $19.08. Deutsche Bank also revised its longer-term revenue forecast to $15.87 billion by fiscal 2030.

Tencent signed a $7B, five-year lease with Oracle (ORCL) for 100,000 AI chips, per Financial Times. The deal covers Oracle data centers in Southeast Asia, with Tencent paying 30% upfront. Oracle's Q1 revenue grew 30% to $19.3B, with cloud infrastructure revenue up 121%. ORCL stock is down 52% over the past year, with a $238 price target.